Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 276-279

  Bontant, T ^a   Sedlacek P ^b   Balduzzi, A ^c   Gaspar, B ^d   Cesaro, S ^e   Einsele, H ^f   Peters, C ^g   Dalle, J H ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Policlinico GB Rossi   (Italy)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; QUESTIONNAIRES; TRANSPLANTATION CONDITIONING;

EID: 84893767360     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.164     Document Type: Article

References (35)

1. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
2. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95: 2240-2245.
3. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol 2004; 65: 416-422.
4. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102: 4255-4260.
5. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
6. Miller W, Flynn P, McCullough J, Balfour Jr. HH, Goldman A, Haake R et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986; 67: 1162-1167.
7. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J 2009; 6: 4.
8. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282.
9. Baldanti F, Lilleri D, Gerna G. Human cytomegalovirus load measurement and its applications for pre-emptive therapy in patients undergoing hematopoietic stem cell transplantation. Hematol Oncol 2008; 26: 123-130.
10. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-5719.
11. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
12. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9: 258-268.
13. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
14. Matthes-Martin S, Lion T, Aberle SW, Fritsch G, Lawitschka A, Bittner B et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 2003; 31: 803-808.
15. Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002; 35: 999-1004.
16. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 633-638.
17. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008; 15: 4-12.
18. Canpolat C, Culbert S, Gardner M, Whimbey E, Tarrand J, Chan KW. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 589-593.
19. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18: 233-246.
20. Ljungman P, Deliliers GL, Platzbecker U, Matthes-Martin S, Bacigalupo A, Einsele H et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001; 97: 388-392.
21. Ljungman P, Oberg G, Aschan J, Ehrnst A, Lonnqvist B, Pauksen K et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 565-568.
22. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988; 318: 70-75.
23. Sharland M, Luck S, Griffiths P, Cotton M. Antiviral therapy of CMV disease in children. Adv Exp Med Biol 2011; 697: 243-260.
24. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Am Soc Hematol 2011; 2011: 305-309.
25. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
26. Guerin V, Dalle JH, Pedron B, Ouachee-Chardin M, Yakouben K, Baruchel A et al. Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation. Bone Marrow Transplant 2010; 45: 442-449.
27. Peggs KS, Mackinnon S. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum Immunol 2004; 65: 550-557.
28. Passweg JR, Baldomero H, Gratwohl A, Bregni M, Cesaro S, Dreger P et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012; 47: 906-923.
29. Gimeno C, Solano C, Latorre JC, Hernandez-Boluda JC, Clari MA, Remigia MJ et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008; 46: 3311-3318.
30. Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010; 6: 711-721.
31. Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. N Microbiol 2011; 34: 157-164.
32. Fryer JF, Heath AB, Anderson R, Minor PD, WHOB Units, Group CS et al. Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays. World Health Organization: Geneva, Switzerland, 2010.
33. Avery RK, Adal KA, Longworth DL, Bolwell BJ. A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and pre-emptive therapy. Bone Marrow Transplant 2000; 26: 763-767.
34. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
35. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009; 22: 76-98.